Satellos Reports Positive Six-Month Interim Data for SAT-3247 in Adult DMD Patients
MSLE sits 54% above its 52-week low of $5.44.
Summary
Satellos Bioscience reported positive six-month interim clinical data for its lead drug candidate, SAT-3247, in adult Duchenne Muscular Dystrophy patients, showing improvements in muscle composition and function.
Key Events · Product Development and Regulatory · MSLE
-
Positive Interim Clinical Data
Six-month data from the TRAILHEAD study showed reduced muscle fat fraction, increased upper limb effort, and stable strength in adult DMD patients treated with SAT-3247.
-
Favorable Safety Profile
SAT-3247 was well tolerated with no serious adverse events and 100% compliance, consistent with previously reported data.
-
Reduced Muscle Damage Biomarker
Mean creatine kinase (CK) levels, a biomarker of muscle damage, declined by 38% from baseline through month 6.
-
Upcoming Milestones
The company expects to complete enrollment for the BASECAMP pediatric study in Q3 2026, with topline data anticipated in Q4 2026, and TRAILHEAD 12-month primary readout also in Q4 2026.
Analysis · MSLE · Life Sciences
The filing details encouraging six-month interim data from the TRAILHEAD study for SAT-3247 in adults with Duchenne Muscular Dystrophy. Despite the small sample size, the consistent improvements in muscle fat fraction, total effort, and stable strength, alongside reduced muscle damage biomarkers and a favorable safety profile, suggest potential biological activity. These results are particularly significant given the advanced muscle loss in adult DMD patients and provide positive momentum for the ongoing Phase 2 BASECAMP study in pediatric patients, with topline data expected in Q4 2026.
How filings like this one have moved
In the 30 days to Aug 22, 2026, 37.4% of the 3517 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MSLE was trading at $8.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.